The Temple Thrombosis Research Center is a formally established research institute within the medical school dedicated to advancing our understanding of the etiology, pathogenesis, diagnosis and treatment of arterial and venous thrombosis. In the SCOR, investigators in this center are examining the role of platelets, plasma coagulation factors, vascular wall cells, and neutrophils in thrombogenesis. As normal biochemical and physiological mechanisms are elucidated, departures from these patterns of response provide the knowledge of pathological processes that are necessary for development of appropriate diagnostic tests. The increasing understanding of the abnormalities underlying the thrombotic process makes possible the rational development of therapeutic interventions to inhibit or prevent thrombogenesis in a vessel. Each project in the present proposal has the potential to indicate an appropriate inhibitory drug or other therapeutic approaches to prevent platelet aggregation, fibrin formation or the consequences of vessel wall injury, all of which contribute to the formation of an obstructing thrombus. We have divided the research activities of this SCOR into three areas corresponding to three broad research objectives. The first objective (A) is to study the interaction of the cell and molecular biology of contract system activation and inhibition which encompasses the projects of Drs. Colman and Schmaier on kininogen and C1 inhibitor. The second goal is to investigate two major aspects of platelet function, coagulant activity and calcium modulation, as reflected in the projects of Drs. Walsh and Rao. The third task is to elucidate the mechanism of action of naturally occurring inhibitors, the arginine serpins and the disintegrins, including the investigations of Drs. Bock and Niewiarowski. The supporting core units A-C represent common facilities for protein structure led by Dr. Jameson, administrative organization supervised by Dr. Colman, and research resources under the aegis of Dr. Stewart.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
1P50HL045486-01
Application #
3106893
Study Section
Special Emphasis Panel (SRC (O1))
Project Start
1991-05-01
Project End
1996-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Temple University
Department
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Ho, D H; Baglia, F A; Walsh, P N (2000) Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domain. Biochemistry 39:316-23
Tan, L; Kowalska, M A; Romo, G M et al. (1999) Identification and characterization of endothelial glycoprotein Ib using viper venom proteins modulating cell adhesion. Blood 93:2605-16
Kowalska, M A; Tan, L; Holt, J C et al. (1998) Alboaggregins A and B. Structure and interaction with human platelets. Thromb Haemost 79:609-13
Danen, E H; Marcinkiewicz, C; Cornelissen, I M et al. (1998) The disintegrin eristostatin interferes with integrin alpha 4 beta 1 function and with experimental metastasis of human melanoma cells. Exp Cell Res 238:188-96
Ahmad, S S; Wong, M Y; Rawala, R et al. (1998) Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry 37:1671-9
Musial, J; Gluszko, P; Undas, A et al. (1998) Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor. Thromb Res 89:253-61
Miyamoto, S; Marcinkiewicz, C; Edmunds Jr, L H et al. (1998) Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost 80:225-30
McLane, M A; Marcinkiewicz, C; Vijay-Kumar, S et al. (1998) Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 219:109-19
Ho, D H; Badellino, K; Baglia, F A et al. (1998) A binding site for heparin in the apple 3 domain of factor XI. J Biol Chem 273:16382-90
Scandura, J M; Zhang, Y; Van Nostrand, W E et al. (1997) Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2. Biochemistry 36:412-20

Showing the most recent 10 out of 101 publications